Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma

Lancet Oncol. 2022 Oct;23(10):e443. doi: 10.1016/S1470-2045(22)00574-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Doxorubicin / adverse effects
  • Humans
  • Leiomyosarcoma* / drug therapy
  • Trabectedin

Substances

  • Doxorubicin
  • Trabectedin